News
December 2009 - GCP Inspection by the MHRA
TMC had a routine MHRA GCP Inspection and two inspectors reviewed our procedures. Their report has now been issued with no critical and no major findings. We are very pleased to have passed this important hurdle, our first inspection. A routine MHRA pharmacovigilance inspection is also planned for March 2010.
November 2009 - New offices
After 9 years in the same office, TMC’s expansion has required a move to something bigger. The new office is in Hampshire, UK, not far from the old one, but offers much more space and better facilities for our growing staff. Our new address and telephone numbers are at the foot of this page.
October 2009 - TMC now Preferred Provider for one of the Top Five global pharmaceutical companies based in Geneva
After a formal assessment process, TMC has been granted preferred provider status for one of the top five global pharmaceutical companies, working for their Consumer Health Division. The first project under the new arrangement will be to chair and report an Expert Advisory Board in Switzerland.
September 2009 - TMC presents at FDA ODAC
TMC Chief Medical Officer, Dr Mike Matthews, presented the safety data on Gloucester Pharmaceuticals’ new HDAC inhibitor romidepsin at the FDA’s Oncology Drugs Advisory Committee (ODAC) meeting in Bethesda on September 4th 2009 and answered the Committee’s questions on the safety data, see http://www.drugs.com/nda/romidepsin_090902.html.
FDA subsequently approved romidepsin (‘Istodax’) in cutaneous T-cell lymphoma on 6 November 2009 see http://www.medicalnewstoday.com/articles/170146.php.
August 3rd 2009 - New UK office administrator appointed by TMC
We are pleased to announce that Michelle Nickless has joined the company to run all office functions at TMC headquarters in Hampshire, UK. Michelle comes from an IT administration background with one of the world’s largest IT system suppliers.
August 2009 - New website launched
With the growth of TMC Pharma Services Ltd from The Matthews Consultancy Ltd it was time for a complete revamp of our website to better reflect the wider range and greater scope of our services. We hope you will take a look at the result (and let us know if we have left anything out).
8 July 2009 - TMC takes over as temporary Marketing Authorisation Holder (MAH) in the UK of Osmoprep™
Osmoprep ™ is indicated for cleansing of the bowel when required as a preparation for certain diagnostic procedures such as colonoscopy. Osmoprep™ 1500mg Tablets will be available shortly (PL08637/0017).
19 June 2009 - TMC takes over as temporary Marketing Authorisation Holder (MAH) for Vasovist in the EU
Vasovist (gadofosveset trisodium) is for diagnostic use only, it is indicated for contrast-enhanced magnetic resonance angiography for visualization of abdominal or limb vessels in patients with suspected or known vascular disease. See http://www.emea.europa.eu/humandocs/Humans/EPAR/vasovist/vasovist.htm
January 2009 - TMC launched – a new company growing from The Matthews Consultancy
Clients who have been used to working with The Matthews Consultancy Ltd in the past will be interested to see that our company has grown and changed a lot in the last couple of years. TMC Pharma Services Ltd is still led by the same team but has expanded to offer not only consultancy services but a wide range of drug development and marketing support services through a global network of Associates.